ACSL4 and cancer: For example, prioritizing the targeting of ALOX12 in p53-mutated tumors and designing ACSL4-LPCAT3 dual-target inhibitors in GPX4-low expressing cancers may break through the efficacy bottleneck of existing ferroptosis inducers, pushing metabolic targeted therapy into a new era of “signal pathway decoding” (Chu et al., 2019).